Accessibility Menu
Provexis Plc logo

Provexis Plc(LSE) PXS

Market Cap£24.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)-67%
5 Year+27%
1 Year+43%
1 Month-5%
£0.01
-6.25%
-0.00Today
Provexis Plc last closing stock price
MetricPriceDate
Last closeGBX 1.052026-09-02
Provexis Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.94%GBX 1.022026-08-26
1 month-4.55%GBX 1.102026-08-03
3 month-4.55%GBX 1.102026-06-04
Year to date+16.67%GBX 0.902025-12-31
1 year+42.86%GBX 0.742025-09-01
3 year+61.54%GBX 0.652023-09-01
5 year+26.89%GBX 0.832021-09-03
Since inception-66.94%GBX 0.032005-06-24

Provexis Plc Financials at a Glance

Market Cap

£24.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£2.07M

Net Income (TTM)

-£1.08M

EPS (TTM)

-£0.00

P/E Ratio

-35.00

Dividend

£0.00

Beta (Volatility)

-0.11 (Low)

Price

£0.01

Volume

159,335

Open

£0.01

Previous Close

£0.01

Daily Range

£0.01 - £0.01

52-Week Range

£0.01 - £0.02

Estimated Earnings Date

Dec 29, 2025

PXS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Provexis Plc

Provexis plc is a healthcare company specializing in the development, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. The company is known for its innovative product, Fruitflow, a tomato extract aimed at reducing abnormal blood clot formation, which is linked to serious cardiovascular issues.

Products and Services
  • Fruitflow: A unique tomato extract available in syrup and powder formats
  • Fruitflow + Omega-3: A capsule supplement promoting healthy blood circulation
  • Collaboration with By-Health Co., Ltd. for product distribution
Growth Outlook
  • Recent quarterly revenue of £364,369 shows potential for recovery
  • Strategic partnerships may enhance market reach and product offerings
  • Focus on functional foods aligns with growing health-conscious consumer trends
Financial Highlights
  • Trailing twelve months (TTM) revenue of £1,364,000 indicates a steady market presence
  • Current ratio of 3.65 suggests strong liquidity and financial health
  • Operating cash flow improved to £17,210 in the latest quarter
Provexis plc operates in the specialized drug manufacturing sector, focusing on innovative health solutions. The company's flagship product, Fruitflow, is designed to address cardiovascular health, a growing concern among consumers. With a strategic collaboration with By-Health Co., Ltd., Provexis is positioned to expand its market presence and product distribution. The growth outlook appears promising, as recent quarterly revenue figures indicate a potential recovery trajectory. The company's focus on functional foods aligns well with the increasing consumer demand for health-oriented products. Financially, the company demonstrates a solid liquidity position, as evidenced by a current ratio of 3.65, which indicates the ability to cover short-term liabilities effectively. Recent quarterly performance shows an improvement in operating cash flow, suggesting better management of resources and operational efficiency. Overall, Provexis plc presents an intriguing opportunity for investors interested in the healthcare and wellness sectors, particularly in functional foods and dietary supplements.
AI Generated • Aug 19, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

2

CEO

Ian Ford

Website

www.provexis.com

Headquarters

Reading, BR RG1 1AZ, GB

PXS Financials

Key Financial Metrics (TTM)

Gross Margin

49.24%

Operating Margin

-103.94%

Net Income Margin

-69.30%

Return on Equity

-49.45%

Return on Capital

-34.55%

Return on Assets

-71.72%

Earnings Yield

-2.86%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£24.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.35B

Volume

159.34K

Avg. Volume

1.17M

Financials (TTM)

Gross Profit

£848.45K

Operating Income

-£1.09M

EBITDA

-£1.08M

Operating Cash Flow

-£657.35K

Capital Expenditure

£0.00

Free Cash Flow

-£657.35K

Cash & ST Invst.

£523.35K

Total Debt

£0.00

Provexis Plc Performance Analysis

Provexis Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-03-31GBP 426,168N/A
20232023-03-31GBP 389,916-8.5%
20242024-03-31GBP 801,964105.7%
20252025-03-31GBP 1,292,24461.1%
Provexis Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-03-316.9%
Q22024-09-3089.5%
Q42025-03-31-35.5%
Q22025-09-30-28.1%
Provexis Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-03-31GBP -0.00N/A
20232023-03-31GBP -0.00100.0%
20242024-03-31GBP -0.0050.0%
20252025-03-31GBP -0.00-33.3%
Provexis Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-03-31-100.0%
Q22024-09-3050.0%
Q42025-03-31N/A
Q22025-09-30100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

£364.37K

-6.0%

Gross Profit

£169.38K

+23.0%

Gross Margin

46.49%

N/A

Market Cap

£24.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£12.32M

N/A

Employees

2

N/A

Net Income

-£310.23K

-16.1%

EBITDA

-£307.15K

-29949.0%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

£523.35K

+64.2%

Total Debt

£0.00

N/A

Accounts Receivable

£274.52K

-10.1%

Inventory

£43.97K

-69.9%

Long Term Debt

£0.00

N/A

Short Term Debt

£0.00

N/A

Return on Assets

-71.72%

N/A

Return on Invested Capital

-1.48%

N/A

Free Cash Flow

-£187.53K

-205.1%

Operating Cash Flow

-£187.53K

-205.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ABDX.LAbingdon Health Plc
£0.11+0.00%
IHC.LInspiration Healthcare Group plc
£0.19-1.04%
COG.LCambridge Cognition Holdings Plc
£0.31+0.00%
IXI.LIXICO plc
£0.08+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$224.41+0.03%
PCGPG&E
$13.33-0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.37+0.00%
NUNu Holdings
$15.40+0.07%

Questions About PXS

What is the current price of Provexis Plc?

Provexis Plc is trading at £0.01 per share.

What is the 52-week range for Provexis Plc?

Over the past 52 weeks, Provexis Plc has traded between £0.01 and £0.02.

How much debt does Provexis Plc have?

As of the most recent reporting period, Provexis Plc reported total debt of £0.00.

How much cash does Provexis Plc have on hand?

Provexis Plc reported £708.09K in cash and cash equivalents in its most recent financial results.

What is Provexis Plc’s dividend yield?

Provexis Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services